Drug – bio-affecting and body treating compositions – Fermentate of unknown chemical structure – Having a known elemental analysis
Patent
1998-07-10
2000-05-30
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Fermentate of unknown chemical structure
Having a known elemental analysis
435171, A61K 3570, C12P 102
Patent
active
060688394
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to TKR1912-I and TKR1912-II, which are antibiotics of use as therapeutic agents for fungal infections diseases, a method for their production, and microorganisms producing said antibiotics.
BACKGROUND ART
Fungi are known to cause a variety of infectious diseases in man, animals, and plants. In man, for instance, they cause superficial mycosis affecting the skin, oral cavity, etc. and systemic mycosis affecting the viscera, brain, etc. They cause similar infections in pet and domestic animals as well. Furthermore, fungi inflict various hazardous effects on plants such as orchard trees and vegetables.
As the principal pathogenic fungi causing systemic mycosis in man, those of the genera Candida, Cryptococcus, and Aspergillus, among others, are known. As to superficial mycosis, candidal species affecting the skin, oral cavity, and vagina and trichophytons infecting the skin of the extremities are regarded as the major pathogenic fungi. Besides those fungi, many other fungi exist in the environment and are suspected to contaminate the animal and vegetable kingdoms.
As antimycotics of use for the prevention and treatment of such fungal infections and contaminations, only a very few are known. As therapeutic drugs for systemic mycosis in man and animals, for instance, amphotericin B, flucytosine, miconazole, and fluconazole can be mentioned. However, those compounds are not fully satisfactory in potency, toxic potential, or antifungal spectrum, thus being not impeccable as therapeutic drugs.
DISCLOSURE OF THE INVENTION
In view of the above-mentioned prior art, the present invention has for its object to provide a novel class of antibiotics which are of value as therapeutic agents for fungal infections.
In their search for a novel antibiotic, the inventors of the present invention isolated a large number of microorganisms from the natural kingdom, isolated the antibiotics they produced, and scrutinized their biological properties. As a result, they discovered that the culture broth of a strain of microorganism of the genus Aureobasidium contained an antibiotic having antifungal activity against pathogenic fungi inclusive of Candida albicans and Cryptococcus neoformans. Accordingly the inventors isolated this antibiotic and studied its physicochemical properties. As a result, they discovered that the above antibiotic is actually comprised of two novel substances having distinct physicochemical characteristics and named then TKR1912-I and TKR1912-II. The present invention provides the above-mentioned antibiotics TKR1912-I and TKR1912-II and a method for their production.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a chart showing the ultraviolet absorption spectrum of the antifungal substance TKR1912-I, in which the ordinate represents wavelength (nm);
FIG. 2 is a chart showing the infrared absorption spectrum of the antifungal substance TKR1912-I, in which the abscissa represents wave number (cm.sup.-1);
FIG. 3 is a chart showing the ultraviolet absorption spectrum of the antifungal substance TKR1912-II, in which the ordinate represents wavelength (nm);
FIG. 4 is a chart showing the infrared absorption spectrum of the antifungal substance TKR1912-II, in which the abscissa represents wavenumbers (cm.sup.-1);
FIG. 5 is a chart showing the .sup.1 H-NMR spectrum of the antifungal substance TKR1912-I, in which the abscissa represents chemical shift (ppm);
FIG. 6 is a chart showing the .sup.13 C-NMR spectrum of the antifungal substance TKR1912-I, in which the abscissa represents chemical shift (ppm);
FIG. 7 is a chart showing the .sup.1 H-NMR spectrum of the antifungal substance TKR1912-II, in which the abscissa represents chemical shift (ppm);
FIG. 8 is a chart showing the .sup.13 C-NMR spectrum of the antifungal substance TKR1912-II, in which the abscissa represents chemical shift (ppm);
FIG. 9 is a HPLC chart of the antifungal substance TKR1912-I showing its elution position, in which the ordinate represents relative UV intensity at 220 nm and the abscissa repre
Kato Ikunoshin
Kazutoh Takesako
Koyama Eiko
Masuda Tomoko
Yoshikawa Yoshie
Goldberg Jerome D.
Takara Shuzo Co. Ltd.
LandOfFree
Antibiotics TKR1912-I and TKR1912-II and process for producing t does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibiotics TKR1912-I and TKR1912-II and process for producing t, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibiotics TKR1912-I and TKR1912-II and process for producing t will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1908130